Navigation Links
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets
Date:6/17/2011

NMS.

Tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with RISPERDAL® and similar medications. TD includes uncontrollable movements of the face, tongue, and other parts of the body. The risk of developing TD and the chance that it will become permanent is thought to increase with the length of therapy and the overall dose taken by the patient. This condition can develop after a brief period of therapy at low doses, although this is much less common. There is no known treatment for TD, but it may go away partially or completely if therapy is stopped.

RISPERDAL® and similar medications can raise the blood levels of a hormone known as prolactin, causing a condition known as hyperprolactinemia. Blood levels of prolactin remain elevated with continued use. Some side effects seen with these medications include the absence of a menstrual period; breasts producing milk; the development of breasts by males; and the inability to achieve an erection. The connection between prolactin levels and side effects is unknown.

High blood sugar and diabetes have been reported with RISPERDAL® and similar medications. If the person being treated has diabetes or risk factors such as being overweight or a family history of diabetes, blood sugar testing should be performed at the beginning and throughout treatment. Complications of diabetes can be serious and even life threatening. If signs of high blood sugar or diabetes develop, such as being thirsty all the time, going to the bathroom a lot, or feeling weak or hungry, contact your doctor.

RISPERDAL® should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizures.

Some people taking RISPERDAL® may feel faint or lightheaded when they stand up or sit up too quickly. By standing up or sitting up slowly and following your healthcare professional's dosing inst
'/>"/>

SOURCE Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
2. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
3. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
4. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
5. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
6. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
7. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference
8. Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months
9. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
10. Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
11. Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Novation, the leading health care supply chain ... value-added reseller (VAR) national contracts that expand its portfolio ... at lower costs. These include manufacturer product and service ... assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 2011 Columbia Laboratories, Inc. (Nasdaq: CBRX ... ), today announced the publication of Phase III PROCHIEVE® ... Ultrasound in Obstetrics & Gynecology , the leading peer-reviewed ... & Gynecology. The published results indicate ...
... SAN DIEGO, April 6, 2011 ... a leading global medical technology company, today announced ... of pharmaceutical waste, helping hospitals reduce cost, improve ... (Photo:   http://photos.prnewswire.com/prnh/20110406/LA78173 ) (Logo:   ...
Cached Medicine Technology:Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results 2Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results 3Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results 4Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results 5Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results 6Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results 7Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results 8CareFusion Acquires Technology for Sorting and Managing Dangerous Pharmaceutical Waste 2CareFusion Acquires Technology for Sorting and Managing Dangerous Pharmaceutical Waste 3
(Date:4/22/2014)... 22 April 2014. The latest scientific advances and emerging ... Failure 2014, the main annual meeting of the Heart ... (ESC). Journalists will also hear breaking news on acute ... Heart Failure, which is part of the main congress. ... Athens, Greece, at the Megaron Athens International Conference Centre ...
(Date:4/22/2014)... have demonstrated the first size-based form of chromatography ... of living cells. This unique physical approach to ... to whether a cell lives or dies, remains ... through conventional microscopy. , "We,ve developed membrane-embedded nanodot ... both probe and manipulate membrane assemblies, including signaling ...
(Date:4/22/2014)... exposed to trauma, illness, alcohol or other drug abuse, ... brain cells that can go awry and activate conditions ... of autism. , Until now, it has been unclear ... a developing brain. Past studies have shown that when ... abuse or she experiences some trauma or illness, her ...
(Date:4/22/2014)... fiction: In enemy territory, activate your cloaking device. And ... to the immune system. Now scientists at Harvard,s Wyss ... tactics to build the first DNA nanodevices that survive ... the way for smart DNA nanorobots that could use ... doctors can today; target drugs to tumors, or even ...
(Date:4/22/2014)... can help doctors better identify patients who are at ... prevent the often deadly condition, suggest data from a ... Anesthesiology . , Affecting nearly 200,000 Americans a ... failure of the lungs caused by a number of ... infection. High-risk patients can develop ARDS after surgery. ARDS ...
Breaking Medicine News(10 mins):Health News:The world's largest heart failure congress 2Health News:The world's largest heart failure congress 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3Health News:Life stressors trigger neurological disorders, researchers find 2Health News:Cloaked DNA nanodevices survive pilot mission 2Health News:Cloaked DNA nanodevices survive pilot mission 3Health News:New tool helps doctors better predict, prevent deadly respiratory failure 2
... ... Victory: Cortical Concepts Wins ,Wharton Business Plan Competition Michelson Grand Prize with ,Device ... with Private Sales for Co-eds, , ... Philadelphia, PA (PRWEB) April 29, 2010 -- The ...
... ... of Science and Technology Policy, will bring together leaders in open innovation , ... Washington, DC (Vocus) -- ... Open Grant Making”, a public-private strategy session jointly hosted by the White House Office ...
... team of researchers at the University of Georgia and Emory ... from the National Institutes of Health to study the neurobiological ... relapse. "Drug abuse is closely linked to stress, ... is preventing the relapse caused by stress," said Philip Holmes, ...
... ... grant from the Ontario Ministry of Research and Innovation’s Biopharmaceutical Investment Program (BIP). ... facility in Mississauga, Ontario, Canada. , ... Toronto, ON (Vocus) April 30, 2010 -- Therapure Biopharma Inc. ...
... mutation impacts how the brain communicates with limbs, researcher says ... that causes a phenomenon known as mirror movements has been ... unable to move one side of their body without moving ... right hand, the same movement occurs unintentionally in the left ...
... ... Association, a non-profit organization, has developed a unique caregiver testing program to measure the ... and consumers. , ... Indianapolis, Ind. (Vocus) April 29, 2010 -- The National Private Duty Association (NPDA), a ...
Cached Medicine News:Health News:Wharton Business Plan Competition Michelson Grand Prize Winners Announced 2Health News:Wharton Business Plan Competition Michelson Grand Prize Winners Announced 3Health News:Prize4Life Featured in Major Innovation/Prize National Conference 2Health News:Prize4Life Featured in Major Innovation/Prize National Conference 3Health News:UGA, Emory to study how exercise may prevent drug abuse relapse 2Health News:Therapure Awarded $4.2 Million BIP Grant from the Ontario Government 2Health News:Scientists Find Cause of Involuntary Mirror Movements 2Health News:Association Advocates Testing for Home Care Workers 2
30 cm - 11 3/4, packages 5 pcs....
Outer diameter 8.0 mm, with graduation....
Width 3 (76 mm), length 6 3/4 (171 mm). Pattie Tray attaches to long or short arm....
Length-9 (229 mm) Tapered retractor blades....
Medicine Products: